Dr. Michael Konstan, MD

NPI: 1568482537
Total Payments
$148,712
2024 Payments
$27.92
Companies
12
Transactions
179

Payment Breakdown by Category

Consulting$92,637 (62.3%)
Other$44,317 (29.8%)
Travel$7,542 (5.1%)
Food & Beverage$2,447 (1.6%)
Research$1,691 (1.1%)
Education$78.15 (0.1%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $92,637 53 62.3%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $44,318 28 29.8%
Travel and Lodging $7,542 42 5.1%
Food and Beverage $2,447 42 1.6%
Unspecified $1,691 10 1.1%
Education $78.15 4 0.1%

Payments by Type

General
$147,021
169 transactions
Research
$1,691
10 transactions

Top Paying Companies

Company Total Records Latest Year
Vertex Pharmaceuticals Incorporated $42,674 63 $0 (2023)
Insmed, Inc. $41,708 45 $0 (2023)
Chiesi USA, Inc. $34,334 45 $0 (2021)
PTC Therapeutics, Inc. $6,400 2 $0 (2018)
ABBVIE INC. $6,050 6 $0 (2023)
Mylan Specialty L.P. $5,621 5 $0 (2024)
Genentech, Inc. $5,122 7 $0 (2018)
Novartis Pharmaceuticals Corporation $3,081 1 $0 (2018)
Nabriva Therapeutics, plc $2,203 1 $0 (2021)
Merck Sharp & Dohme Corporation $1,488 2 $0 (2020)

Payment History by Year

Year Amount Transactions Top Company
2024 $27.92 1 Mylan Specialty L.P. ($27.92)
2023 $20,657 25 Insmed, Inc. ($9,465)
2022 $35,958 23 Insmed, Inc. ($26,958)
2021 $11,611 10 Vertex Pharmaceuticals Incorporated ($3,500)
2020 $2,507 6 Insmed, Inc. ($2,030)
2019 $11,348 24 Chiesi USA, Inc. ($11,317)
2018 $41,083 59 Vertex Pharmaceuticals Incorporated ($17,279)
2017 $25,519 31 VERTEX PHARMACEUTICALS INCORPORATED ($10,681)

All Payment Transactions

179 individual payment records from CMS Open Payments — Page 1 of 8

Date Company Product Nature Form Amount Type
06/20/2024 Mylan Specialty L.P. TOBI PODHALER (Drug) Food and Beverage In-kind items and services $27.92 General
Category: Aminoglycosides
12/13/2023 Vertex Pharmaceuticals Incorporated Consulting Fee Cash or cash equivalent $4,691.25 General
09/18/2023 Insmed, Inc. Consulting Fee Cash or cash equivalent $500.00 General
09/18/2023 Insmed, Inc. Consulting Fee Cash or cash equivalent $375.00 General
08/18/2023 Insmed, Inc. Consulting Fee Cash or cash equivalent $707.00 General
07/13/2023 Insmed, Inc. Consulting Fee Cash or cash equivalent $208.35 General
06/08/2023 Insmed, Inc. Consulting Fee Cash or cash equivalent $500.00 General
04/12/2023 Insmed, Inc. Cash or cash equivalent $250.00 Research
04/12/2023 Insmed, Inc. Cash or cash equivalent $225.00 Research
04/12/2023 Insmed, Inc. Cash or cash equivalent $125.00 Research
04/12/2023 Insmed, Inc. Cash or cash equivalent $125.00 Research
04/12/2023 Insmed, Inc. Cash or cash equivalent $80.00 Research
04/12/2023 Insmed, Inc. Cash or cash equivalent $75.00 Research
02/09/2023 Mylan Specialty L.P. Consulting Fee Cash or cash equivalent $3,000.00 General
02/06/2023 Insmed, Inc. Consulting Fee Cash or cash equivalent $1,000.00 General
02/06/2023 Insmed, Inc. Consulting Fee Cash or cash equivalent $500.00 General
02/06/2023 Insmed, Inc. Consulting Fee Cash or cash equivalent $170.00 General
02/06/2023 Insmed, Inc. Consulting Fee Cash or cash equivalent $170.00 General
02/06/2023 Insmed, Inc. Consulting Fee Cash or cash equivalent $165.00 General
02/06/2023 Insmed, Inc. Consulting Fee Cash or cash equivalent $165.00 General
02/06/2023 Insmed, Inc. Consulting Fee Cash or cash equivalent $125.00 General
01/05/2023 Insmed, Inc. Consulting Fee Cash or cash equivalent $1,500.00 General
01/05/2023 Insmed, Inc. Consulting Fee Cash or cash equivalent $1,000.00 General
01/05/2023 Insmed, Inc. Consulting Fee Cash or cash equivalent $1,000.00 General
01/05/2023 Insmed, Inc. Consulting Fee Cash or cash equivalent $500.00 General

Research Studies & Clinical Trials

Study Name Company Amount Records
Epidemiologic Study of Cystic Fibrosis ICON Protocol 130-044 Statistical analysis of data previously obtained from a multicenter, longitudinal study Study IDZ0595n of patients with cystic fibrosis Genentech, Inc. $696.54 1
Statistical analysis of data previously obtained from a multicenter, longitudinal study Study IDZ0595n of patients with cystic fibrosis. Genentech, Inc. $114.00 3

About Dr. Michael Konstan, MD

Dr. Michael Konstan, MD is a Pediatric Pulmonology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568482537.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Konstan, MD has received a total of $148,712 in payments from pharmaceutical and medical device companies, with $27.92 received in 2024. These payments were reported across 179 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($92,637).

Practice Information

  • Specialty Pediatric Pulmonology
  • Location Cleveland, OH
  • Active Since 07/20/2006
  • Last Updated 11/17/2010
  • Taxonomy Code 2080P0214X
  • Entity Type Individual
  • NPI Number 1568482537

Products in Payments

  • PERTZYE (Drug) $30,385
  • SYMDEKO (Drug) $17,243
  • BETHKIS (Drug) $3,927
  • ORKAMBI (Drug) $3,552
  • TOBI PODHALER (Drug) $3,109
  • Arikayce (Drug) $2,750
  • ZERBAXA (Drug) $1,488
  • Non-Covered Product (Drug) $696.54
  • Pulmozyme (Biological) $114.00
  • TOBI Podhaler (Drug) $97.42
  • Creon (Drug) $31.13
  • ZENPEP (Drug) $30.22
  • BRONCHITOL (Drug) $23.16
  • CREON (Drug) $19.03

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatric Pulmonology Doctors in Cleveland